Aldesleukin is under clinical development by Iltoo Pharma and currently in Phase III for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase III drugs for Amyotrophic Lateral Sclerosis have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Aldesleukin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Aldesleukin overview

ILT-101 is under development for the treatment of autoimmune and inflammatory diseases including type I diabetes, acute respiratory distress syndrome due to Coronavirus disease 2019 (COVID-19), relapsing remitting multiple sclerosis, recurrent miscarriage, systemic lupus erythematosus, allergic rhino-conjunctivitis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Behcet disease, Wegener granulomatosis, Crohn's disease, ulcerative colitis, autoimmune hepatitis, sclerosing cholangitis, Gougerot-sjogren, systemic sclerosis, idiopathic thrombocytopenic purpur, bipolar disorder and amyotrophic lateral sclerosis. It is administered by subcutaneous route and formulated as powder for solution as an injection. The drug candidate is a human recombinant Interleukin-2 which acts by targeting interleukin receptor2. It was also under development for Takayasu disease.

For a complete picture of Aldesleukin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.